IDEAYA Biosciences (IDYA) Accounts Payables (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Accounts Payables data on file, last reported at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 17.61% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $20.7 million (up 17.61% YoY), and the FY2025 full-year result was $17.6 million, up 14.03% from the prior year.
• Accounts Payables improved to $20.7 million in Q1 2026, from $17.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.7 million in Q1 2026 to a low of $3.4 million in Q1 2022.
• A 5-year average of $10.5 million and a median of $6.6 million in 2023 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 180.3% in 2025, while the deepest fall reached 8.71% in 2025.
• Tracing IDYA's Accounts Payables over 5 years: stood at $4.3 million in 2022, then surged by 54.16% to $6.6 million in 2023, then jumped by 133.72% to $15.4 million in 2024, then grew by 14.03% to $17.6 million in 2025, then advanced by 17.93% to $20.7 million in 2026.
• Business Quant data shows IDYA's Accounts Payables at $20.7 million in Q1 2026, $17.6 million in Q4 2025, and $18.4 million in Q3 2025.